Advertisement

BIOACTIVE GLASS S53P4: a new opportunity for the treatment in the diabetic foot osteomyelitis

Published:April 27, 2018DOI:https://doi.org/10.1016/j.ejim.2018.04.015
      Diabetes mellitus is one of the major public health problems worldwide. With the aging of the population, improvements in living standards, and changes in lifestyle, the prevalence of the disease is growing rapidly. There have been many studies regarding high prevalence of diabetes and diabetes complication among patients admitted to Internal Medicine Wards and costs for diabetic patients, both in North America and Europe. Most have shown that the medical costs of diabetes are responsible for a very high proportion of total healthcare expenditure, with the proportion of costs increasing year by year [
      • Solli O.
      • Jenssen T.
      • Kristiansen I.S.
      Diabetes: cost of illness in Norway.
      ,
      • Tunceli O.
      • et al.
      Cost of diabetes: comparison of disease attributable and matched cohort cost estimation methods.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Solli O.
        • Jenssen T.
        • Kristiansen I.S.
        Diabetes: cost of illness in Norway.
        BMC Endocr Disord. 2010; 10: 15
        • Tunceli O.
        • et al.
        Cost of diabetes: comparison of disease attributable and matched cohort cost estimation methods.
        Curr Med Res Opin. 2010; 26: 1827-1834
        • Xiaoyuan B.A.O.
        • et al.
        Hospitalization costs and complications in hospitalized patients with type 2 diabetes mellitus in Beijing, China.
        J Diabetes. 2017; 9: 405-411
        • Hicks C.W.
        • et al.
        158 burden of infected diabetic foot ulcers on hospital admissions and costs.
        Ann Vasc Surg. 2016; 33: 149-158
        • Eneroth M.
        • Larsson J.
        • Apelqvist J.
        Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis.
        J Diabetes Complications. 1999; 13: 254-263
        • Lipsky B.A.
        • et al.
        Diagnosing and treating diabetic foot infections.
        Diabetes Metab Res Rev. 2004; 20: S56-S64
        • Prompers L.
        • et al.
        High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study.
        Diabetologia. 2007; 50: 18-25
        • Lipsky B.A.
        • et al.
        Executive summary: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Most DFIs require some surgical intervention, ranging from minor (debridement) to major (resection, amputation). Infectious Diseases Society of America.
        Clin Infect Dis. 2012 Jun; 54: 1679-1684
        • Drago L.
        • et al.
        Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study.
        BMC Infect Dis. 2013; 13
        • Romanò C.L.
        • et al.
        Bioactive glass S53P4 versus antibiotic loaded calcium-based bone substitutes for the treatment of chronic osteomyelitis: a retrospective, comparative study.
        Bone Joint J. 2014; 96-B: 845-850